Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.

Plaza-Menacho I, Morandi A, Robertson D, Pancholi S, Drury S, Dowsett M, Martin LA, Isacke CM.

Oncogene. 2010 Aug 19;29(33):4648-57. doi: 10.1038/onc.2010.209. Epub 2010 Jun 7.

PMID:
20531297
2.

GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.

Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I, Isacke CM.

Cancer Res. 2013 Jun 15;73(12):3783-95. doi: 10.1158/0008-5472.CAN-12-4265. Epub 2013 May 6.

3.

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.

J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.

4.

HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.

Shah N, Jin K, Cruz LA, Park S, Sadik H, Cho S, Goswami CP, Nakshatri H, Gupta R, Chang HY, Zhang Z, Cimino-Mathews A, Cope L, Umbricht C, Sukumar S.

Cancer Res. 2013 Sep 1;73(17):5449-58. doi: 10.1158/0008-5472.CAN-13-1178. Epub 2013 Jul 5.

5.

Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.

Spanheimer PM, Park JM, Askeland RW, Kulak MV, Woodfield GW, De Andrade JP, Cyr AR, Sugg SL, Thomas A, Weigel RJ.

Clin Cancer Res. 2014 Apr 15;20(8):2115-25. doi: 10.1158/1078-0432.CCR-13-2221. Epub 2014 Feb 13.

6.

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.

Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H.

J Biol Chem. 2001 Mar 30;276(13):9817-24. Epub 2001 Jan 3.

8.

Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.

Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, Covington KR, Tsimelzon A, Fuqua SA.

Breast Cancer Res Treat. 2015 Nov;154(2):225-37. doi: 10.1007/s10549-015-3609-7. Epub 2015 Oct 20.

9.

MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.

Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB.

Oncogene. 2002 Jun 6;21(25):4000-8.

10.

The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.

Shrivastav A, Bruce M, Jaksic D, Bader T, Seekallu S, Penner C, Nugent Z, Watson P, Murphy L.

Breast Cancer Res. 2014 May 22;16(3):R49. doi: 10.1186/bcr3660.

11.

Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.

Ito T, Kamijo S, Izumi H, Kohno K, Amano J, Ito K.

Breast Cancer Res Treat. 2012 May;133(1):145-59. doi: 10.1007/s10549-011-1731-8. Epub 2011 Aug 24.

PMID:
21863258
12.

Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.

Busch S, Sims AH, Stål O, Fernö M, Landberg G.

Cancer Res. 2015 Apr 1;75(7):1457-69. doi: 10.1158/0008-5472.CAN-14-1583.

13.

Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.

Bentin Toaldo C, Alexi X, Beelen K, Kok M, Hauptmann M, Jansen M, Berns E, Neefjes J, Linn S, Michalides R, Zwart W.

BMC Cancer. 2015 Aug 14;15:588. doi: 10.1186/s12885-015-1591-4.

14.

Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.

Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G.

J Natl Cancer Inst. 2006 May 17;98(10):671-80.

PMID:
16705121
15.

MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation.

Liang YK, Zeng, Xiao YS, Wu Y, Ouyang YX, Chen M, Li YC, Lin HY, Wei XL, Zhang YQ, Kruyt FA, Zhang GJ.

Cancer Lett. 2017 Feb 1;386:65-76. doi: 10.1016/j.canlet.2016.11.004. Epub 2016 Nov 9.

16.

Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.

Stender JD, Nwachukwu JC, Kastrati I, Kim Y, Strid T, Yakir M, Srinivasan S, Nowak J, Izard T, Rangarajan ES, Carlson KE, Katzenellenbogen JA, Yao XQ, Grant BJ, Leong HS, Lin CY, Frasor J, Nettles KW, Glass CK.

Mol Cell. 2017 Mar 16;65(6):1122-1135.e5. doi: 10.1016/j.molcel.2017.02.008.

PMID:
28306507
17.

VAV3 mediates resistance to breast cancer endocrine therapy.

Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA.

Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664.

18.

The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.

Scherbakov AM, Sorokin DV, Tatarskiy VV Jr, Prokhorov NS, Semina SE, Berstein LM, Krasil'nikov MA.

IUBMB Life. 2016 Apr;68(4):281-92. doi: 10.1002/iub.1481. Epub 2016 Feb 19.

19.

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.

Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.

Breast Cancer Res. 2014 Jan 23;16(1):R12. doi: 10.1186/bcr3604.

20.

MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.

Bobustuc GC, Smith JS, Maddipatla S, Jeudy S, Limaye A, Isley B, Caparas ML, Constantino SM, Shah N, Baker CH, Srivenugopal KS, Baidas S, Konduri SD.

Mol Med. 2012 Sep 7;18:913-29. doi: 10.2119/molmed.2012.00010. Erratum in: Mol Med. 2012;18: doi/10.2119/molmed.2012.00006.erratum.

Supplemental Content

Support Center